Biodegradable glucosaminemuramyl peptides for apoptosis...

Details Biodegradable glucosaminemuramyl peptides for apoptosis... Biodegradable glucosaminemuramyl peptides for apoptosis...

2006-09-26

2006-09-26

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07112564

ABSTRACT:
The endopeptidase hydrolysis of cross link peptide bond of the peptidoglycans results in release of the novel glucosaminemuramyl tri, tetra, penta, hexa, and octapeptides. Their structure is defined by specific endopeptidase cleavage as well as genus of gram positive bacteria. They are potent cytoprotective agents capable of inhibiting of TNF alpha cytotoxicity.

REFERENCES:
patent: 4395399 (1983-07-01), Ovchinnikov et al.
patent: 4545932 (1985-10-01), Takase
patent: 5834435 (1998-11-01), Slesarev
patent: 6506388 (2003-01-01), Shionoya
patent: 2001/0034325 (2001-10-01), Slesarev
Ghuysen, Use of Bacteriolytic Enzymes in Determination of Wall Structure and Their Role in Cell Metabolism, Bacteriological Reviews, Dec. 1968, pp. 425-464.
See http://www.chemqmul.ac.uk/iumb/enzyme/EC3/4/24/75.html, printed May 31, 2005, p. 1.
Guinand, et al., Enzymatic Obtention of Biologically Active Glycopeptides from Actinomadura R 39, Biological Properties of Peptidoglycan, Second, Proceeding of the International Workshop, 1986, Meeting Date 1985, pp. 389-394.
DNA Isolation Protocols Biomolecule Teaching Guide, Patrick, Supplement IVA, Mar. 4, 2003, pp. 1 and 1-8, http://www.rpc.msoe.edu/sepa/preview//sec4/4-a-6.htm, printed May 31, 2005.
Fountoulakis, et al. Effect of Strong Detergents and Chaotropes on the Detection of Proteins in Two-Dimensional Gels, Electrophoresis, 2001, 22, 1593-1602.
Sharmar, Anker SD. Cytokines, apoptosis(abstract) cachexia: the potential for TNF. antagonism. Int. J. Cardiology, 2002; 85:161-71.
Argiles JM. Int. J. Biochem Cell Biol Abstract 2003, 35: 405-409.
Castellanos M. Stroke, 2002 Abstract v33:982-987.
Cusack MR. Amer. Coll Cardiology Abstract 2002, 39: 1917-1923.
Agnoletti L. Circulation, 1999 v. 100: 1983-1991.
Affords Molecular Pathology (Abstract) 2002, v. 53 : 55-63.
Kurzrock R Cancer, 2001 v92 : 1684-1688 (Abstract).
McGuire SO Experimental Neurology, 2001, V169, 219-30 (Abstract).
Barone F.C. Stroke, 1997, v. 28: 1233-1244.
Armstrong L. Thorax, 1997, V.52 : 442-446.
Ridker P., Circulation, 2000, v. 101 p. 2149-2153.
Jaeckhke H., J. Immunogy, 1998 v. 160 : 3480-3486.
Smarmavk Expert Opin Investig (Abstract) Drugs, 2003, 12: 139-152.
Stammch, Circulation, v. 101 suppl l. 350-351.
Zanotti S., Expert Opin Investig Drugs,2002 v. 11: 1061-75 (Abstract).
Niermaus A., Intensive Care Med. 2003 v.21 (Abstract).
Yan R, Zhonghua Zhen Xing Shao Shang Nai 1997, B 368-72 (Abstract).
Jarrar D., AmJ. Physiol Lung Cell Mol Physiol 2002, 283: 799-805 (Abstract).
Serteser M., J. Surg Res, 2002, 107: 234-40 (Abstract).
Oxman T., Amj. Physiol Heart Cre Physiol,278 M 1717-24.

Affiliated with

Also associated with

Rating

Biodegradable glucosaminemuramyl peptides for apoptosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biodegradable glucosaminemuramyl peptides for apoptosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biodegradable glucosaminemuramyl peptides for apoptosis... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3619887